NCT01848561
Brief summary
This is a registry study to evaluate the long-term safety and effectiveness of an active drug in patients with moderately to severely active UC who are treated as recommended in the product label.
Observational study
Age:
From 18 Years to 99 Years.
Inclusion Criteria:
- For enrollment into the HUMIRA treatment group; adult patients with moderately to
severely active UC who has been prescribed HUMIRA therapy according to routine
clinical practice and meets one of the following:
1. Is currently taking HUMIRA therapy and has received at least 8 weeks of
therapy; OR
2. Is entering after participation in an Abbott or AbbVie sponsored UC study and;
has received continuous HUMIRA therapy since initiation of therapy
- For enrollment into the IMM treatment group; adult patients with moderately to
severely active UC who has been prescribed IMM therapy, is currently taking IMM
therapy, and has received at least 12 consecutive weeks of IMM therapy
- Patients capable of and willing to grant authorization for use/disclosure of data
being collected and provided to AbbVie prior to any registry-related data being
collected, and to comply with the requirements of the Registry protocol
Exclusion Criteria:
- Patients on IMM therapy without a concurrent biologic if they cannot continue to be
treated with IMM therapy or
- Patients who are being treated with any investigational agents and/or approved
biologics other than Humira.
